CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 1993; 43:177
doi: 10.3322/canjclin.43.3.177
© 1993 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haas, G. P.
Right arrow Articles by Pontes, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haas, G. P.
Right arrow Articles by Pontes, J. E.

CA: A Cancer Journal for Clinicians, Vol 43, Issue 3 177-187, Copyright © 1993 by American Cancer Society

ARTICLES

Immunotherapy of renal cell carcinoma

G. P. Haas, G. G. Hillman, B. G. Redman and J. E. Pontes
Department of Urology, Wayne State University School of Medicine, Detroit, Michigan.

Immunologic approaches to the therapy of metastatic renal cell carcinoma have provided moderate improvement in response rates for a disease that is extremely resistant to all forms of treatment. This article reviews recent clinical efforts using immunotherapy for renal cell carcinoma, including the adoptive transfer of cytotoxic killer cells and/or the use of biologic response modifiers, such as interferon and interleukin-2.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. J. Dudderidge, K. Stoeber, M. Loddo, G. Atkinson, T. Fanshawe, D. F. Griffiths, and G. H. Williams
Mcm2, Geminin, and KI67 Define Proliferative State and are Prognostic Markers in Renal Cell Carcinoma
Clin. Cancer Res., April 1, 2005; 11(7): 2510 - 2517.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
R. Katz-Brull, N. M. Rofsky, M. M. Morrin, I. Pedrosa, D. J. George, M. D. Michaelson, R. P. Marquis, M. Maril, C. Noguera, and R. E. Lenkinski
Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy
Am J Physiol Renal Physiol, April 1, 2005; 288(4): F637 - F641.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-M. Tourani, C. Pfister, N. Tubiana, M. Ouldkaci, G. Prevot, V. Lucas, S. Oudard, M. Malet, P. Cottu, J.-M. Ferrero, et al.
Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design--The Subcutaneous Administration Propeukin Program Cooperative Group
J. Clin. Oncol., November 1, 2003; 21(21): 3987 - 3994.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Donskov, H. von der Maase, R. Henriksson, U. Stierner, P. Wersall, H. Nellemann, K. Hellstrand, K. Engman, and P. Naredi
Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-{alpha} in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study
Ann. Onc., March 1, 2002; 13(3): 441 - 449.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by American Cancer Society.